Trial Profile
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 06 Dec 2016 Results from this and other five studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 13 May 2016 Status changed from completed to discontinued.
- 11 May 2016 Status changed from active, no longer recruiting to completed.